Cargando…

Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy

OBJECTIVE: To investigate anti-neurofascin 155 (NF155) antibody-positive chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Sera from 50 consecutive CIDP patients diagnosed in our clinic, 32 patients with multiple sclerosis, 40 patients with other neuropathies including 26 with Guill...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Hidenori, Yamasaki, Ryo, Hiwatashi, Akio, Oka, Nobuyuki, Kawamura, Nobutoshi, Matsuse, Dai, Kuwahara, Motoi, Suzuki, Hidekazu, Kusunoki, Susumu, Fujimoto, Yuichi, Ikezoe, Koji, Kishida, Hitaru, Tanaka, Fumiaki, Matsushita, Takuya, Murai, Hiroyuki, Kira, Jun-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603379/
https://www.ncbi.nlm.nih.gov/pubmed/26478896
http://dx.doi.org/10.1002/acn3.248
_version_ 1782394906187137024
author Ogata, Hidenori
Yamasaki, Ryo
Hiwatashi, Akio
Oka, Nobuyuki
Kawamura, Nobutoshi
Matsuse, Dai
Kuwahara, Motoi
Suzuki, Hidekazu
Kusunoki, Susumu
Fujimoto, Yuichi
Ikezoe, Koji
Kishida, Hitaru
Tanaka, Fumiaki
Matsushita, Takuya
Murai, Hiroyuki
Kira, Jun-ichi
author_facet Ogata, Hidenori
Yamasaki, Ryo
Hiwatashi, Akio
Oka, Nobuyuki
Kawamura, Nobutoshi
Matsuse, Dai
Kuwahara, Motoi
Suzuki, Hidekazu
Kusunoki, Susumu
Fujimoto, Yuichi
Ikezoe, Koji
Kishida, Hitaru
Tanaka, Fumiaki
Matsushita, Takuya
Murai, Hiroyuki
Kira, Jun-ichi
author_sort Ogata, Hidenori
collection PubMed
description OBJECTIVE: To investigate anti-neurofascin 155 (NF155) antibody-positive chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Sera from 50 consecutive CIDP patients diagnosed in our clinic, 32 patients with multiple sclerosis, 40 patients with other neuropathies including 26 with Guillain–Barré syndrome (GBS)/Fisher syndrome, and 30 healthy controls were measured for anti-NF antibodies by flow cytometry using HEK293 cell lines stably expressing human NF155 or NF186. Four additional CIDP patients with anti-NF155 antibodies referred from other clinics were enrolled for clinical characterization. RESULTS: The positivity rate for anti-NF155 antibodies in CIDP patients was 18% (9/50), who all showed a predominance of IgG4 subclass. No other subjects were positive, except one GBS patient harboring IgG1 anti-NF155 antibodies. No anti-NF155 antibody carriers had anti-NF186 antibodies. Anti-NF155 antibody-positive CIDP patients had a significantly younger onset age, higher frequency of drop foot, gait disturbance, tremor and distal acquired demyelinating symmetric phenotype, greater cervical root diameter on magnetic resonance imaging neurography, higher cerebrospinal fluid protein levels, and longer distal and F-wave latencies than anti-NF155 antibody-negative patients. Marked symmetric hypertrophy of cervical and lumbosacral roots/plexuses was present in all anti-NF155 antibody-positive CIDP patients examined by neurography. Biopsied sural nerves from two patients with anti-NF155 antibodies demonstrated subperineurial edema and occasional paranodal demyelination, but no vasculitis, inflammatory cell infiltrates, or onion bulbs. Among anti-NF155 antibody-positive patients, treatment responders more frequently had daily oral corticosteroids and/or immunosuppressants in addition to intravenous immunoglobulins than nonresponders did. INTERPRETATION: Anti-NF155 antibodies occur in a subset of CIDP patients with distal-dominant involvement and symmetric nerve hypertrophy.
format Online
Article
Text
id pubmed-4603379
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-46033792015-10-16 Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy Ogata, Hidenori Yamasaki, Ryo Hiwatashi, Akio Oka, Nobuyuki Kawamura, Nobutoshi Matsuse, Dai Kuwahara, Motoi Suzuki, Hidekazu Kusunoki, Susumu Fujimoto, Yuichi Ikezoe, Koji Kishida, Hitaru Tanaka, Fumiaki Matsushita, Takuya Murai, Hiroyuki Kira, Jun-ichi Ann Clin Transl Neurol Research Articles OBJECTIVE: To investigate anti-neurofascin 155 (NF155) antibody-positive chronic inflammatory demyelinating polyneuropathy (CIDP). METHODS: Sera from 50 consecutive CIDP patients diagnosed in our clinic, 32 patients with multiple sclerosis, 40 patients with other neuropathies including 26 with Guillain–Barré syndrome (GBS)/Fisher syndrome, and 30 healthy controls were measured for anti-NF antibodies by flow cytometry using HEK293 cell lines stably expressing human NF155 or NF186. Four additional CIDP patients with anti-NF155 antibodies referred from other clinics were enrolled for clinical characterization. RESULTS: The positivity rate for anti-NF155 antibodies in CIDP patients was 18% (9/50), who all showed a predominance of IgG4 subclass. No other subjects were positive, except one GBS patient harboring IgG1 anti-NF155 antibodies. No anti-NF155 antibody carriers had anti-NF186 antibodies. Anti-NF155 antibody-positive CIDP patients had a significantly younger onset age, higher frequency of drop foot, gait disturbance, tremor and distal acquired demyelinating symmetric phenotype, greater cervical root diameter on magnetic resonance imaging neurography, higher cerebrospinal fluid protein levels, and longer distal and F-wave latencies than anti-NF155 antibody-negative patients. Marked symmetric hypertrophy of cervical and lumbosacral roots/plexuses was present in all anti-NF155 antibody-positive CIDP patients examined by neurography. Biopsied sural nerves from two patients with anti-NF155 antibodies demonstrated subperineurial edema and occasional paranodal demyelination, but no vasculitis, inflammatory cell infiltrates, or onion bulbs. Among anti-NF155 antibody-positive patients, treatment responders more frequently had daily oral corticosteroids and/or immunosuppressants in addition to intravenous immunoglobulins than nonresponders did. INTERPRETATION: Anti-NF155 antibodies occur in a subset of CIDP patients with distal-dominant involvement and symmetric nerve hypertrophy. John Wiley & Sons, Ltd 2015-10 2015-09-11 /pmc/articles/PMC4603379/ /pubmed/26478896 http://dx.doi.org/10.1002/acn3.248 Text en © 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Ogata, Hidenori
Yamasaki, Ryo
Hiwatashi, Akio
Oka, Nobuyuki
Kawamura, Nobutoshi
Matsuse, Dai
Kuwahara, Motoi
Suzuki, Hidekazu
Kusunoki, Susumu
Fujimoto, Yuichi
Ikezoe, Koji
Kishida, Hitaru
Tanaka, Fumiaki
Matsushita, Takuya
Murai, Hiroyuki
Kira, Jun-ichi
Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
title Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
title_full Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
title_fullStr Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
title_full_unstemmed Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
title_short Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy
title_sort characterization of igg4 anti-neurofascin 155 antibody-positive polyneuropathy
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603379/
https://www.ncbi.nlm.nih.gov/pubmed/26478896
http://dx.doi.org/10.1002/acn3.248
work_keys_str_mv AT ogatahidenori characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT yamasakiryo characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT hiwatashiakio characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT okanobuyuki characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT kawamuranobutoshi characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT matsusedai characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT kuwaharamotoi characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT suzukihidekazu characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT kusunokisusumu characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT fujimotoyuichi characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT ikezoekoji characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT kishidahitaru characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT tanakafumiaki characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT matsushitatakuya characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT muraihiroyuki characterizationofigg4antineurofascin155antibodypositivepolyneuropathy
AT kirajunichi characterizationofigg4antineurofascin155antibodypositivepolyneuropathy